Dendreon (DNDNQ) Stock Price, News & Analysis

Company Overview

Dendreon was a biotechnology company focused on developing personalized cellular immunotherapies for cancer. Its principal product was Provenge (sipuleucel-T), an autologous immunotherapy designed to stimulate a patient’s immune system to target prostate cancer cells. Provenge received approval from the U.S. Food and Drug Administration in 2010 for certain men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

The Provenge treatment is manufactured using a patient’s own immune cells. These cells are collected through an outpatient procedure, processed and activated with a prostate cancer antigen, and then returned to the patient. The product represented Dendreon’s primary commercial offering and was marketed primarily in the United States, where the company operated specialized manufacturing and treatment-support infrastructure.

Dendreon filed for Chapter 11 bankruptcy protection in 2014 following financial and operational challenges. Its assets and Provenge business were subsequently sold and reorganized under new ownership, while the original public company became associated with the OTC Markets symbol DNDNQ. Provenge has continued to be associated with Dendreon Pharmaceuticals, although the original publicly traded Dendreon Corporation is no longer operating as an independent public company.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2014
• Today: 9/28/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DNDNQ
• Previous Symbol: NASDAQ:DNDN
• CIK: N/A
• Web: www.dendreon.com
• Phone: +1-206-2197815
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A